207 related articles for article (PubMed ID: 16640124)
1. The impact of subjective well-being under neuroleptic treatment on compliance and remission.
de Millas W; Lambert M; Naber D
Dialogues Clin Neurosci; 2006; 8(1):131-6. PubMed ID: 16640124
[TBL] [Abstract][Full Text] [Related]
2. Subjective well-being under the neuroleptic treatment and its relevance for compliance.
Naber D; Karow A; Lambert M
Acta Psychiatr Scand Suppl; 2005; (427):29-34. PubMed ID: 15943008
[TBL] [Abstract][Full Text] [Related]
3. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
4. Subjective effects of antipsychotic drugs and their relevance for compliance and remission.
Naber D
Epidemiol Psichiatr Soc; 2008; 17(3):174-6. PubMed ID: 18924553
[TBL] [Abstract][Full Text] [Related]
5. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
Naber D; Moritz S; Lambert M; Pajonk FG; Holzbach R; Mass R; Andresen B
Schizophr Res; 2001 May; 50(1-2):79-88. PubMed ID: 11378316
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
[TBL] [Abstract][Full Text] [Related]
7. Subjective well-being and quality of life under atypical antipsychotic treatment.
Karow A; Naber D
Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
9. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
[TBL] [Abstract][Full Text] [Related]
10. Good tolerability equals good results: the patient's perspective.
Naber D; Karow A
Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S391-6. PubMed ID: 11587886
[TBL] [Abstract][Full Text] [Related]
11. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
Naber D
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
[TBL] [Abstract][Full Text] [Related]
12. Patients' subjective experiences of antipsychotics: clinical relevance.
Hellewell JS
CNS Drugs; 2002; 16(7):457-71. PubMed ID: 12056921
[TBL] [Abstract][Full Text] [Related]
13. [Viewpoint of schizophrenic patients: a European survey].
Courtet P
Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
[TBL] [Abstract][Full Text] [Related]
14. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
Lambert M; Schimmelmann BG; Karow A; Naber D
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Löffler W; Kilian R; Toumi M; Angermeyer MC
Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
[TBL] [Abstract][Full Text] [Related]
16. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review.
Vothknecht S; Schoevers RA; de Haan L
Aust N Z J Psychiatry; 2011 Mar; 45(3):182-92. PubMed ID: 21438745
[TBL] [Abstract][Full Text] [Related]
17. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
[TBL] [Abstract][Full Text] [Related]
18. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.
Cabeza IG; Amador MS; López CA; González de Chávez M
Schizophr Res; 2000 Jan; 41(2):349-55. PubMed ID: 10708344
[TBL] [Abstract][Full Text] [Related]
19. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
[TBL] [Abstract][Full Text] [Related]
20. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
Staring AB; Mulder CL; Duivenvoorden HJ; De Haan L; Van der Gaag M
Schizophr Res; 2009 Aug; 113(1):27-33. PubMed ID: 19525092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
